Premarket Approval (PMA) Agreement with FDA for the Medical Device Companies - Webinar by GlobalCompliancePanel

GlobalCompliancePanel, Online Training, 161 Mission Falls Lane, Suite 216, Fremont, CA 94539, USA
2013-12-12

Overview: The Premarket Approval (PMA) pathway is complex. The PMA application needs to provide a reasonable assurance that the device is safe and effective for its intended use (21 USC 360e(d)(1)(A)). To do this, companies must submit valid scientific evidence (21 CFR 860.7(c)), typically derived from a clinical study. The application also needs to include documents demonstrating compliance with the Quality Systems Regulations (QSRs) (21 CFR Part 820). The PMA must also include draft labeling, information regarding product composition, preclinical data, and a summary of relevant literature (21 CFR 814.20(b)). 

Once a PMA is submitted, FDA will reach a filing decision within 45 days (21 CFR 814.42(a)). The agency then has 180 days in which to complete the review. If FDA identifies major deficiencies, the 180-day review clock starts again. Before approving a PMA, FDA will generally conduct a preapproval inspection to evaluate QSR compliance. 

Why Should You Attend :

To gain a fundamental understanding of the Premarket Approval (PMA) process. 

Areas Covered in the Session:

Intended Use
Scientific Evidence
QSR Compliance
Product Labeling
FDA Review Times

Who Will Benefit:

Regulatory Affairs
Research and Development
Investigators
Regulatory professionals working in the medical device field